Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros








Base de dados
Intervalo de ano de publicação
1.
Eur Rev Med Pharmacol Sci ; 27(12): 5421-5430, 2023 06.
Artigo em Inglês | MEDLINE | ID: mdl-37401277

RESUMO

OBJECTIVE: Since 1967, when the osteoinduction properties of autogenous demineralized dentin matrix were discovered, autologous tooth grafts have been advocated as a viable option to autologous or heterologous bone graft. Tooth graft materials may be extracted from the patient's whole tooth using a granulating device. The aim of this study was to examine the size of granules obtained by the Tooth Transformer (TT)® device, using a laser instrument with high precision. MATERIALS AND METHODS: The TT® device can obtain bone graft material in a short period from an extracted tooth. The resulting material can act as an osteoconductive scaffold, providing a mineral substrate during resorption, including platelet growth factors and morphogenetic proteins. Different studies have investigated the dimension and behavior of various graft material particles, since the size of the grafted particles may play a role in osteogenesis and bone regeneration. RESULTS: Different dimensions of granules are available: small (< 400 µm), medium (400 µm-1,000 µm) and large (1,000 µm-2,000 µm). From 4.03 µm to 100 µm the percentage of granules was 14.52 ± 1.93%. A larger part of the granules was up to 100 µm, while 85.47 ± 1.93% of the granules were from 100 µm to 1,000 µm. CONCLUSIONS: 85% of the granules produced were in accordance with the dimensions suggested in the literature.


Assuntos
Dente , Humanos , Regeneração Óssea , Osso e Ossos , Osteogênese , Extração Dentária , Transplante Ósseo
2.
Acta Neurol (Napoli) ; 13(3): 255-60, 1991 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-1833956

RESUMO

15 patients with chronic cerebrovascular disease were studied using carotid Doppler and B-mode echography, transcranial Doppler, EEG and clinical evaluation before and 3 and 6 months after treatment with mesoglycan sulphate at doses of 96 mg/day per os. A subjective improvement was reported by 7 out of 15 patients while no significant variations in Doppler, TCD, echographic and EEG data were observed. During treatment no side effects or laboratory abnormalities were found.


Assuntos
Transtornos Cerebrovasculares/tratamento farmacológico , Glicosaminoglicanos/uso terapêutico , Idoso , Idoso de 80 Anos ou mais , Doença Crônica , Feminino , Humanos , Masculino
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA